Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
12-30-2021 - … Number 0000875045-21-000061 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 30, 2021 Document Date Dec 28, … Number 0000875045-21-000061 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 30, 2021 Document Date Dec 28, …
12-28-2021 - … Number 0000875045-21-000060 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 28, 2021 Document Date Dec 23, … Number 0000875045-21-000060 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 28, 2021 Document Date Dec 23, …
Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation
December 23, 2021 - … Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that lecanemab, an investigational … devastating disease with few treatment options. Eisai and Biogen are committed to bring new treatment options to people …
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
December 22, 2021 - … CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) … (PMDA) in Japan to agree on additional data requirements. Biogen and Eisai remain committed to bringing aducanumab to … for medical advice about side effects. As of October 2017, Biogen and Eisai Co., Ltd. are collaborating on the global …
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
December 20, 2021 - … Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease Biogen Announces Reduced Price for ADUHELM® to Improve Access … CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that, effective …
Update on Regulatory Submission for Aducanumab in the European Union
December 17, 2021 - … the European Union December 17, 2021 News Release General Biogen to seek re-examination following CHMP negative opinion … CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) … the negative trend vote of the committee in November 2021. Biogen will seek a re-examination of the opinion by the CHMP. …
Update on the Phase 4 Confirmatory Study of ADUHELM®
December 16, 2021 - … CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, … Sciences and interim Head of Research & Development at Biogen. “Together with EMBARK, Biogen’s redosing study, and the ICARE AD study, we aim to … CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, …
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
December 14, 2021 - … Biogen and TheraPanacea Announce New Collaboration with the … Digital Health for Personalized Medicine in Neuroscience Biogen and TheraPanacea Announce New Collaboration with the … for personalized and earlier treatment in neurology Biogen to gain exclusive rights to TheraPanacea technology in …
12-10-2021 - … Number 0001127602-21-030720 Filing Group 3,4,5 Issuer BIOGEN INC. Filer Kramer Robin Filing Date Dec 10, 2021 … Number 0001127602-21-030720 Filing Group 3,4,5 Issuer BIOGEN INC. Filer Kramer Robin Filing Date Dec 10, 2021 …
12-10-2021 - … Number 0000875045-21-000059 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 10, 2021 Document Date Dec 9, … Number 0000875045-21-000059 Filing Group 3,4,5 Issuer BIOGEN INC. Filer BIOGEN INC. Filing Date Dec 10, 2021 Document Date Dec 9, …
